Literature DB >> 20951488

A 90-year-old man with hyperphosphatemia.

Shachi Lovekar1, Joline L T Chen.   

Abstract

Hyperphosphatemia is a common condition in patients with decreased kidney function, and without treatment, it can lead to a variety of clinical consequences. However, the presence of hyperphosphatemia in patients with normal kidney function may be true or spurious. We present a case of pseudohyperphosphatemia in a patient with monoclonal gammopathy. An increased paraprotein level can lead to colorimetric interference of the assay of phosphate measurement and result in spurious hyperphosphatemia. The epidemiologic and clinical characteristics of paraprotein-associated pseudohyperphosphatemia also are reviewed here. Ultrafiltration of paraproteins or deproteinization can help correct the measuring error. Patients with spurious hyperphosphatemia should not be treated with phosphate binders. Clinicians treating patients with monoclonal gammopathy should be aware of this relatively common clinical phenomenon and avoid inappropriate treatment of spurious hyperphosphatemia. Copyright Â
© 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951488     DOI: 10.1053/j.ajkd.2010.07.017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  3 in total

1.  A physiologic-based approach to the evaluation of a patient with hyperphosphatemia.

Authors:  David E Leaf; Myles Wolf
Journal:  Am J Kidney Dis       Date:  2012-08-30       Impact factor: 8.860

2.  Severe hyperphosphatemia in a patient with chronic kidney disease and multiple myeloma-to strengthen the case toward renal replacement therapy?

Authors:  Joerg Latus; Elisabeth Höring; Matthias Voehringer; Dieter Ratge; M Dominik Alscher; Niko Braun
Journal:  Clin Case Rep       Date:  2013-11-13

3.  A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway.

Authors:  Joseph Wang; Beth Vogt; Sidharth Kumar Sethi; Matthew G Sampson; Virginia Vega-Warner; Edgar A Otto; Rupesh Raina
Journal:  Kidney Int Rep       Date:  2017-05-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.